Consistent benefit in Primary and Secondary cohorts.
More absolute benefit in secondary, but that is logical as they are higher risk patients with more events.
Analogous to statins where the curves separate earlier the higher risk the population studied.
Statistically it’s a consistent benefit. Especially given the safety profile is so good, the results of the trial apply equally to primary and secondary cohorts.
News 
Market Data 
Discover 
